IM Therapeutics Is Developing A Novel Targeted Therapy Pipeline in Autoimmune Disease

Monday, October 28, 2019

Type 1 Diabetes Therapy Being Readied for Clinical Trials; Celiac Disease in Drug Development  

Weekly Policy Update: CBSA Co-Hosts Aurora Facility Tour for State Senator Rhonda Fields

Friday, October 25, 2019

This week CBSA partnered with CSL Behring to host state Senator Rhonda Fields for a tour of the CSL Plasma Collection Center in Aurora. On the tour, the collection center managers were able to show Senator Fields the process for donating plasma – which is the first step in the process of manufacturing plasma-derived therapies that patients rely on every day. Plasma-derived therapies replace missing or deficient proteins that allow people to live healthy and more productive lives, including individuals living with alpha-1 disease, primary immunodeficiency disease, hereditary angioedema, and other rare conditions.  

Colorado BioScience Association Welcomes New Appointees to the Board of Directors

Friday, October 25, 2019


SomaLogic significantly expands key strategic collaboration with Novartis

Wednesday, October 23, 2019

Ten-year agreement with Novartis demonstrates broad and deep commitment to accelerating disease and therapeutic-specific insights based on proprietary proteomic technology

Boulder, Colo., USA — SomaLogic, Inc., announced today that it has entered into a new ten-year agreement with its long-time pharmaceutical partner, Novartis, to expand the application of SomaLogic’s leading proteomic technology across the company’s drug discovery and development efforts. The agreement includes plans to analyze at least 250,000 clinical samples from across the Novartis drug development portfolio.

“Our ongoing collaboration with our Novartis colleagues, which began in 2011 and was extended in 2014, has been instrumental in both developing and validating the value of our SomaScan Platform,” said Roy Smythe, M.D., CEO of SomaLogic. “Today, our technology is being used to inform research efforts around the world, promote individual health and wellness, and augment clinical decision-making.”

Under this new agreement, Novartis will expand its access to the SomaScan® Platform, which currently measures approximately 5000 human proteins in a small amount of biological sample. The SomaScan Platform enables Novartis to discover new insights into the biology of disease and the variability of drug response, develop new biomarkers that better target high-responder populations, and then apply these insights to the design of their clinical trials and commercial programs. In turn, this collaboration will assist SomaLogic to grow its clinical proteomics database and expand its growing pipeline of precision health information products. These products are aimed at helping individuals optimize their health and wellness as well as proactively manage many diseases and conditions.

“By continuing our collaboration with SomaLogic and incorporating proteomics into our development programs, alongside our genomics capabilities and deep analysis of our vast historical data resources, we aim to achieve unprecedented insight into human physiology,” said John Tsai, Head of Global Drug Development and Chief Medical Officer at Novartis. “Deciphering the complex interaction of protein networks in the body could unlock an additional therapeutic approach for treating the unmet needs of patients.”

Specific terms of the agreement, including financials and milestones, were not disclosed.


SomaLogic Contact:
Laura S. Mizoue, Ph.D.
Communications Specialist

About SomaLogic
SomaLogic seeks to deliver meaningful and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from the precise, proprietary, and personalized measurement of health-related changes in an individual’s proteins over time. For more information, visit and follow @somalogic on Twitter.

Continue Reading

Weekly Policy Update: CBSA Partners with LivaNova to host Rep. Brianna Titone

Friday, October 18, 2019

This week CBSA partnered with LivaNova to host state Rep. Brianna Titone for a tour and employee town hall at the company’s Arvada facility. It was a great opportunity to showcase the devices that are designed and manufactured at the Colorado plant and highlight the growth and development that is taking place there. We also had the chance to talk to Representative Titone about the life sciences ecosystem in Colorado, and we look forward to continuing to work with her on the issues that matter to our members. 

Regulatory Affairs Professionals Society (RAPS) Welcomes New RAPS Colorado Chapter

Thursday, October 17, 2019

Rockville, MD, USA, Oct. 17, 2019 (GLOBE NEWSWIRE) 

The Regulatory Affairs Professionals Society (RAPS) announced the official launch of the RAPS Colorado Chapter. The group first began as a RAPS-affiliated local networking group before becoming a full chapter. Chapter leaders and other representatives attended RAPS’ recent Regulatory Convergence in Philadelphia, where they were welcomed and acknowledged by RAPS Executive Director Paul Brooks.  

Securisyn Medical Receives FDA 510(k) Clearance for its SolidAIRity™ III Airway Stabilization System

Monday, October 14, 2019

HIGHLANDS RANCH – October 9, 2019 – Securisyn Medical, LLC, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its SolidAIRity™ III Airway Stabilization System (“SolidAIRity™”) for airway management of patients requiring oral intubation. The company, dedicated to making airway management safer, has pioneered the first, fully integrated airway stabilization system designed and patented to provide unmatched airway stability for ventilated patients.

Weekly Policy Update: State Releases Draft Proposal for Public Health Insurance Option

Friday, October 11, 2019


IM Therapeutics Raises $10 Million Financing Co-Led by JDRF T1D Fund and Morningside Ventures

Wednesday, October 09, 2019

IM Therapeutics Raises $10 Million Financing Co-Led by JDRF T1D Fund and Morningside Ventures  

Weekly Policy Update: CBSA Urges Congress to Reject Proposals that Adopt Foreign Price Controls

Friday, October 04, 2019

CBSA is committed to ensuring patients have access to the treatments they need. We appreciate the bipartisan efforts underway by the Trump Administration and Congress to provide patients relief from high out-of-pocket costs, but we are deeply concerned about recent legislative proposals like H.R. 3 that aim to introduce international reference pricing and foreign price controls as a strategy to reduce prescription drug costs.

Foreign countries are able to pay less for drugs by denying access to certain therapies for many patients who need them. In the United States, patients have access to almost 90 percent of new drugs launched since 2011. In the countries that Congress is hoping to mirror with H.R. 3, 50 percent or fewer new therapies are made available to patients. And many times those patients have to wait years before those novel treatments are available. If the United States implemented foreign price controls, patient choice and patient access to innovative therapies would be severely limited.

These recent proposals also jeopardize the innovative biopharmaceutical sector in the United States, a sector that already takes on huge risks and significant investments. The suggestion of foreign price controls will scare away investment in the life sciences, and that money will go to an industry that is less risky and offers a greater return. Capital flowing out of the sector will quickly result in lack of innovation and fewer breakthrough treatments for patients.

In the coming weeks the U.S. House of Representatives is expected to vote on H.R. 3, a proposal that would adopt the health care policies set by foreign countries that lead to fewer innovative medicines and restricted patient access.


Patients deserve access to the life-saving therapies of today and tomorrow.

Continue Reading